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Abstract 
The increasing demand for monoclonal antibodies (mAbs) used for diagnostic and therapeutic 
applications has led to the development of large scale manufacturing processes, with improvements in 
production achieved through continuous optimization of the inherent systems. The number of 
monoclonal antibodies (mAbs) that have already been approved for therapeutic applications and for use 
in clinical trials have significantly increased in the past few years. In view of the side effects and 
limitations of mAbs, several improvements and modifications to monoclonal antibodies have been 
developed. These modifications have facilitated the use of mAbs in various forms of therapeutic 
applications such as treatment of infectious diseases caused by bacterial, viral, fungal and parasitic 
organisms. Monoclonal antibodies have also been applied in the treatment of non-infectious diseases 
such as cancer, immune diseases, arthritis and other disorders resulting from organ transplantation. 
This review highlights mAbs applications in biomedicine, and discusses state-of-the-art technologies 
related to their potential uses. 
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The immune system acts as defence against 
various infectious agents that cause different 
forms of diseases. Two major components are 
the humoral (antibody-mediated) and cellular 
(cell-mediated) immune responses. The humoral 
immune system which comprises B-lymphocytes 
recognizes the type of foreign invading antigens 
and produces specific antibodies against them 
[1]. The two important characteristics of an 
antibody are its specificity to the antigen, and its 
assurance to provide continual resistance to that 
particular type of antigen [2]. Considering their 
unique features, scientists use them for the 
protection of humans against diseases. 
Techniques for in vitro production of antibodies 
was also developed, resulting in the production 
of monoclonal antibodies for diagnostic and 
therapeutic applications [3]. Although antibody 
production has several procedures, the principles 
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generally remain similar to those illustrated in 
Figure 1. 
 
Due to development of new phase of therapy in 
the field of medicine, application of mAbs in the 
treatment of several disease conditions have 
been at the forefront [4]. In 2002, the first human 
mAb for use in clinical practice was approved by 
the Food and Drug Administration of the United 
States. Since then, the mAbs production industry 
has exponentially expanded [5]. The use for 
which mAbs are anticipated determines the exact 
amount required for carrying out the different 
activities. Only  a small amounts of mAb (0.1 g) 
is required for carrying out most research and 
analytic work [6]. 
 
About 30 mAbs were recently accepted for 
clinical use as therapeutics, with several others 
been at various trial stages [7]. Although there 
are current studies that are aimed at improving 
the efficacy of existing mAbs through 
optimisation processes, there still exist some 
limitations one of which include lack of efficient 
mAb generation models [8]. However, despite 
these shortcomings, there remains to exist an 
interest by pharmaceutical companies to develop 
mAbs for clinical use. This is expected to control 
the management of many diseases in future 
base on both clinical and economical 
perspectives [9]. 
 
Types of therapeutic MAbs  
 
Progress in antibody engineering has yielded 
various types of mAbs for application in life 
science and biomedicine. These types of 
antiboies may have similar principles, but 
different targets and applications. In addition, the 
choice of one method over another may be 
guided by several factors, including purpose of 




Figure 1: Steps involved in the production of mAbs 
 
 
Figure 2: Types of therapeutic mAbs and their production methods 
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The use of murine antibodies produced by 
hybridoma technology in human therapy 
(clinical medicine) is limited, attributable to 
differences between the human and rodent 
immune systems. This usually results in 
treatment failure, with the exception of some 
particular circumstances [10] . Murine 
antibodies have mild effects of stimulation of 
cytotoxicity. Thus, their continuous 
administration often results in allergic reactions 
and anaphylactic shock, a result of the 
production of human anti-mouse antibodies 
(HAMA) that invariably attack the administered 
murine mAb and in turn stimulate allergic 
response [6-8]. Anti-CD3 mAb of murine origin 
(OKT-3) was the first therapeutic mAb that was 
approved for clinical use in human medicine. 
However, the mAb failed in treatment of 
transplantation rejection, primarily because it 
causes severe human anti-mouse antibody 
(HAMA) response in patients [11]. In order to 
minimize immunogenic effects of murine mAbs 
in human therapy, murine immunogenic 
components are removed with increased 
efficiency through various approaches  [12].  
 
Since murine mAbs contain foreign protein 
molecules, majority of the early reagents for 
clinical use stimulated unwanted immune 
responses in human patients. Recently, 
molecular biology advances have brought about 
in vitro gene manipulation and subsequent 
expression of these manipulated sequences in 
mammalian, bacterial or fungal cell culture 
protocols. This has thus ensured a better option 
for re-engineering murine mAb to partly 
substitute the rodent antibody fragment with a 
corresponding human antibody sequence.  
 
The total immunogenicity of the mAb is therefore 
reduced without affecting the recognition ability 
of the original antibody [13]. Antibodies resulting 
from humanisation are becoming more relevant 
in the treatment of inflammatory diseases and 
cancer, with several antibody products readily 
available in the market, and others undergoing 




Chimeric antibodies are special types of 
therapeutic antibodies made by the combination 
of genetic ingredients from humans and non-
humans (mice). They are produced through 
manipulation of human constant regions and 
mouse variable regions [15]. These antibodies 
are made up of about 65% human genetic 
component in order to minimize the risk of 
unwanted reactions to foreign antibodies. 
Interestingly, the Food and Drug administration 
has approved some drugs that are based on 
chimeric antibodies for use in human therapy and 
research. The nomenclature for naming chimeric 
mAbs ends with the suffix “ximab” e.g., 




Human mAbs (HMA) have been considered 
natural drugs due to their safety for in vivo 
activities. Modifications in the field of mAb 
technologies has made human mAbs to be 
widely applied in the therapy of various diseases, 
as well as in the development of novel 
immunodiagnostics. A number of about 20 mAb-
drugs, including humanized mice mAbs, have 
been accepted as therapeutic reagents during 
the past few decades. Other mAbs at different 
stages of clinical trial, and controlled by different 
research institution, and/or in collaboration with 
pharmaceutical companies. Use of human mAb 
technologies are not only limited to strategic 
research, but are also of great values in health 
economics [17]. 
 
In humanised antibodies, the hyper variable 
regions are grafted onto human variable domain 
framework. The antibody molecules is nearly 
95% human origin. They are sometimes weaker 
than the parent murine monoclonal antibodies in 
terms of binding with antigens [23]. To increase 
the antibody-antigen binding affinity, techniques 
such as chain-shuffling randomisation can be 
employed to introduce some transformations into 
the complementarity determining region (CDR). 
Examples of FDA-approved humanised 
antibodies include daclizumab, omalizumab, 
alemtuzumab [18]. 
 
Fully human MAbs 
 
Human mAb production by the conventional 
hybridoma techniques is relatively difficult 
because of the stress involved in maintaining 
immortalised cell lines and human hybridomas. It 
is also not feasible for in vivo immunization of 
humans with many different antigens compared 
to the use of animal models [10]. However, 
methods for the production of human mAbs are 
made possible through the expression of 
antibody fragments or single cell variable 
fragment (Fab or ScFv) in bacteria.  Similarly, 
antibody fragments can be displayed on 
filamentous bacteriophages for screening of 
antibody libraries [19,20]. Generation of fully 
human mAbs serves as an alternative to re-
engineer murine mAbs with a source of low 
immunogenic therapeutic antibodies. Most of 
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these drugs were generated using either 
transgenic mice or phage display platforms.  
However, there is still no clear distinction 
between them. 
 
The phage display technique is a well-
established and the most widely used method for 
the development of new human antibodies [21]. 
Alternatively, using transgenic mice containing 
human immunoglobulins may be a strategy for 
the production of human mAbs. Hybridomas that 
produce human antibodies can be generated due 
to a human antibody response resulting from the 
immunization of transgenic mice.  
 
In 2003, Humira®, the first fully human mAb drug 
was lunched for the treatment of rheumatoid 
arthritis [22]. Adalimumab® and Panitimumab® 
are among the marketed fully human therapeutic 
mAbs, while several others are in various stages 
of human clinical testing. Two basic platforms 
have demonstrated to yield active and well-
tolerated therapeutics for the clinical use of fully 
human mAbs. These include transgenic mice 
and phage display platforms [23]. 
 
Transgenic mice platform 
 
Mice that express human antibody repertoires 
through genetic engineering were first reported 
for developing human mAbs using conventional 
cell culture technique [17]. The manipulation of 
endogenous mouse immunoglobulin heavy chain 
and immunoglobulin light chain loci is the result 
of the transchromosonal engineering process. 
Transgenes encrypting human immunoglobulin 
heavy and light chains were introduced. Progress 
has been achieved to express multiple Vgene 
segments by transgenic mice over the past few 
decades, with increase in the number of potential 
repertoires of the recovered mAbs [25].  
 
A  generation of transgenic mice producing 
human mAbs with various heavy chain isotopes 
was achieved; although immune responses are 
sometimes less robust as observed in transgenic 
mice compared to those observed in normal 
mouse strains used in generating mouse mAbs. 
In spite of the above limitations, about six 
different human mAbs produced by transgenesis 
have been approved for marketing and over 50 
human mAbs in clinical trials [17]. This 
expression system of human immunoglobulin in 
transgenic mice prevents the unwanted human 
anti-mouse antibody responses, and maintains 
the merits of murine conventional cell culture 
technique for the generation of potential 
therapeutic reagents [30]. 
 
Phage display platform 
 
The phage display library technology was first 
established in 1985 and has been employed to 
generate a large number of short peptides and 
protein molecules on bacteriophages. This 
allowed the cloning of foreign DNA sequences 
into filamentous bacteriophage and subsequent 
expression of the clones on the surface of the 
phage particles as fusion proteins [24].  This 
technology has been effectively used to select 
antigen-specific variable region genes as well as 
to express purposeful and specific antigen 
fragments [21]. The phage display approach has 
been combined with PCR means to clone 
expressed immunoglobulin variable region cDNA 
repertoires so as to produce diverse libraries of 
phage displayed antibody variable region. This 
could be applied to promptly access target-
specific mAbs, without creating a library of hybrid 
clones [25]. Reverse transcription of messenger 
RNA (mRNA) from B-cells and PCR amplification 
methods were also used to isolate human 
antibodies. Using this same technology, a library 
of different human immunoglobulin heavy chain 
variable (VH) genes and light chain variable (VL) 
gene segments were produced [21]. 
 
The process of combined infection and in vivo 
recombination has been used to display single 
chain fragment variable (scFV) on the surface of 
the phage, to generate large antibody repertoires 
[26]. Identification of specific antibody fragments 
that have good affinities is possible after bio-
panning the phages. The purpose of this is to 
increase the efficacy of antigen-specific scFv, in 
order to enhance the affinity of scFV for antigens, 
and with increased specificity [27]. Similarly, 
phage display technology has been improved, 
and currently, about 35 human mAbs through 
this technology have been certified as 
therapeutic reagents by the Food and Drug 
Administration [22]. 
 
Therapeutic applications of MAbs 
 
Recent advances in genetic engineering have 
made possible efforts to improve the therapeutic 
application of mAbs by identifying new targets 
with improved efficacy for use in clinical practice 
[28]. Their use in immunoprophylaxis or 
immunotherapeutics have been extensively 
applied to infectious diseases, as carriers for 
toxic substances delivery to tumors or as tools 
for identifying, locating and target neoplasms 
[29]. They have also been used in the treatment 
of several types of cancers, immune diseases, 
arthritis and metabolic diseases (Figure 3). Their 
therapeutic applications include cancer therapy, 
human and animal disease therapy, preparation 
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of vaccines, suppression of immune response 




Researchers have shown that mAbs could 
potentially prevent effective colonization of 
Streptococcus mutans in cases of dental caries. 
With the identification of new peptide sub-units 
(epitopes) of Streptococcus mutans, mAbs could 
be used to effectively treat these conditions.  In 
this regard, the endogenous bacteria 
(Streptococcus spp, Lactobacillus spp) are 
colonised to form the main antigen [31]. The 
mucosal defence mechanism is mostly mediated 
by secretory antibodies (sIgA) of the saliva. 
Immunization (vaccination) with purified antigen 
of Streptococcus mutans helps in mobilizing 
antigen-specific immunoglobulins, particularly 
IgA, to salivary glands at induction sites. These 
immunoglobulins (IgA) are produced by specific 
B-cells due to their differentiation and maturation 
in the saliva. Some non-human sources of mAbs 
have also been developed with a lack of side 
effects such as allergic reactions [6]. 
 
Neutralizing antibodies against highly variable 
viral pathogens protects against globally 
circulating viruses [32]. Probing of the 
neutralizing antibody repertoires of HIV donors 
with unusually extensive and effective responses 
yielded 17 new monoclonal antibodies. Many of 
the new mAbs are nearly ten-fold more potent 
compared to the recently described PG9, PG16 
and VRC01 mAbs; and 100-fold more potent 
compared to the original prototype HIV broadly 
neutralizing mAbs [32].These mAbs have 
recognised novel epitopes on envelop 
glycoprotein (gp120), thus revealing new 
alternative targets for vaccine design. Analysis of 
the neutralization by these available mAbs 
reveals that certain mixtures of antibodies could 
offer a more favourable and diverse coverage of 
circulating viruses [32]. 
 
Since mAbs that specifically targets the C9 
binding site of Trichinella spiralis paramyosin 
(Ts-Pmy) would be necessary for use in the 
treatment of Trichinella spiralis infection, mAb 
9G3 was successfully produced. It was found to 
be reactive to recombinant Ts-Pmy, as well as to 
native Ts-Pmy expressed in different stages of 
Trichinella spiralis. The binding of the mAb (9G3) 
to Ts-Pmy was found to actively antagonise the 
binding of Ts-Pmy to human complement C9, 
thus leading to a significant increase in the killing 
of new born larvae in vitro, and a reduced 
infectivity of Trichinella spiralis in the mAb-
treated mice [33]. Conclusion was drawn that the 
mAb (9G3) is both a preventive and therapeutic 




Monoclonal antibody mediated therapy recruits 
cytotoxic cells (monocytes and macrophages) 
through antibody-dependent cell cytotoxicity [34]. 
In the treatment of cancer, mAbs binds 
complement proteins, which thus lead to direct 




Figure 3: Some areas for therapeutic applications of mAbs 
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Some monoclonal antibodies have been reported 
to function in blocking the growth factor by 
binding to, and inhibiting, growth factor receptors, 
in order to effectively arrest the proliferation of 
the tumor cells [42]. Ibritumomab is a monoclonal 
antibody against the CD20 antigen on B-cells for 
the treatment of lymphoma patients; while 
Rituximab (IDEC-C2B8) is a chimeric 
immunoglobulin (IgG) mAb directed against the 
CD20 antigen, which has been reported to be 
effective against B-cells malignancies [22].  
 
Monoclonal antibodies are also modified for the 
delivery of radioisotope (Radioimmunotherapy), 
toxins, cytokines and several other active 
conjugates. Bi-specific mAbs can be designed so 
that their Fab region can target both antigen and 
the effector cells. Report from a study have also 
shown that conjugates, toxins and drugs with 
mAbs can also kill leukemic cells [35]. 
Cetuximab® is a drug used in the treatment of 
certain types of breast cancers and lymphomas 
by blocking HER-1; while Trastuzumab® is 
known to block HER-2 receptors in breast cancer 
[36]. Therapeutic anti-cancer mAbs against 
leukemia are Gemtuzumab® and 
Alemtuzumab®; while Nimotuzumab® and 
Cituximab® are for carcinomas. Bevacizumab is 
another is another drug (mAb) approved by the 
Food and Drug Administration (FDA) for use in 
the therapy of colorectal cancers.  It binds to 
vascular endothelial growth factor (VEGF), 
thereby preventing it from binding to its 
receptors. Vitaxin® is a clinical trial (phase II) 
drug that yielded a better results in shrinking 
solid tumors, with no associated detrimental side 
effects. It is found to binds to a vascular integrin 
(alpha-v/beta-3) present in blood vessels 
supplying tumors but is absent in blood vessels 




Infliximab® and Adalimumab® are available 
monoclonal antibodies used for immune 
diseases, and are effective against rheumatoid 
arthritis, Crohn’s disease and ulcerative colitis 
[6]. They have the tendency to bind and block 
tumor necrosis factor (TNF), TNF-α, and 
Interlukin-2 (IL-2) on activated T-cells which are 
also inhibited by Basiliximab and Daclizumab, 
and thus help prevent acute rejection of kidney 
transplants. Daclizumab® is also a potent mAb-
drug for the treatment of T-cell lymphoma while 
inhibition of human IgE by Omalizumab® is 
valuable in the treatment of various types of 
allergic asthma [38]. OKT3 (Muromonab®, 
Orthoclone®) is the first FDA approved 
therapeutic mAbs (murine IgG2a; CD3-specifc), 
and is currently used in steroid-resistant patients 
who suffer from rejection after solid organ 
transplant. Patients that have received kidney 
transplant are routinely given this drug to induce 
immunosuppression, in order to prevent rejection 
of the foreign tissue. The (OKT-3)  mAb is known 
to attack the T-cells that cause rejection [37]. 
 
In attempts to determine whether monoclonal 
antibodies directed against immune cell 
components responsible for eliciting abnormal 
immune response could be used to treat such 
conditions [39].  Monoclonal antibodies against 
the endotoxins of Escherichia coli have been 
produced and have protected mice from 
bacteremia. They have also been analyzed in 
humans. An anti-T-cell monoclonal antibody that 
remove T-cells from marrow of a donor prior to 
transplantation, is also available which leads to 
reduction in graft-host diseases reduction in 




There is no doubt that metabolic disorders such 
as diabetes, hypercholesterolemia have posed a 
great challenge in human medicine. One of the 
areas where mAbs therapeutics is applied 
includes metabolic disorders. G protein-coupled 
receptors (GPCRs) are implicated in a wide 
variety of metabolic diseases. Thus, scientist 
have used GPCRs membrane fractions as a 
target to produce mAbs for the cure of metabolic 
disorders [41]. Monoclonal antibodies have been 
produced against the human glucagon receptor 
(GCGR) from stable cell lines through a 
transgenic XenoMouse platform. These 
candidate mAbs were shown to display potential 
antagonistic activity in reducing blood glucose 
level with a resultant long-term inhibition of 
GCGR signalling in a mouse model, making 
them effective for controlling diabetic 
hyperglycemia [43]. 
  
Scientists at Harvard School of Public Health 
have recently discovered a new treatment for 
type 2 diabetes through the use of novel mAbs 
targeting secreted fatty acid–binding protein aP2. 
This is an intracellular chaperon protein 
(aP2FABP4) that contributes to hyperglycemia 
by either encouraging hepatic gluconeogenesis 
or countering peripheral insulin action, or by 
combination of both. Fatty acid-binding proteins 
(aP2) have been implicated as a cause of 
pathology of many metabolic diseases in 
humans. Following the experimental treatment of 
mice with aP2-mAb, there was enhanced total 
glucose metabolism, elevated systemic insulin 
sensitivity, lowered fasting blood glucose and 
reduced fat mass and liver steatosis in obese 
mice models. This approach has open a 
Mahmuda et al 
Trop J Pharm Res, March 2017; 16(3): 719  
 
promising paradigm for the treatment of type 2 
diabetes [43].  
 
Among the major risk factors for cardiovascular 
diseases is hypercholesterolemia. The effective 
management of this condition has mainly been 
achieved by statins as first-line therapy, with a 
reported reduction of cholesterol level up to 50 % 
have been reported [44]. Others are 
recommended only if statins are not tolerated. 
Diet-based management is the mainstay of 
therapy in children.  However, as of 2010, no 
study has shown improved clinical outcomes 
[45]. This necessitates the use of other lipid-
lowering agents due to adverse effects in statins 
intolerable patients, especially those with very 
high risk of cardiovascular diseases [46]. 
Increase low-density lipoprotein cholesterol 
(LDL-C) levels have been reported to be a major 
cause of metabolic disorders. Studies that aims 
to inhibit the proprotein convertase 
(subtilisin/kexin) type 9 (PCSK9) to lower LDL-C 
levels have been underway through the 
development of mAbs. Evolocumab and 
Alirocumab were found to be safe and well-
tolerated [47]. Both antibodies were reported to 
substantially reduced the LDL-C level by over 
50%, increase high-density lipoprotein 
cholesterol (HDL-C) level and result in favourable 
changes in other lipids [48].  
 
Problems and future prospects of 
monoclonal antibody therapy 
 
The concept that all therapeutic agents have 
unwanted effects is also applicable to 
monoclonal antibodies. These range from mild to 
severe signs depending on the class they belong 
to, and the route through which they are 
administered [49]. A mild allergic reaction (rash) 
may appear with the first administration of mAbs. 
Clinical signs of weakness, headache, fever, 
diarrhoea, vomiting and nausea, and sometimes 
decreased blood pressure, are common side 
effects.  A mAb used against tumor blood vessel 
growth (Bevacizumab®) can present numerous 
side effects, some of which include renal failure, 
bleeding with poor wound healing and high blood 
pressure. Injection with FDA approved mAb 
(Raxibazumab®) for the treatment of infectious 
inhalational anthrax is also associated with rash 
and severe itching, extreme pain and drowsiness 
[50]. 
 
Only a few out of many FDA regulated mAbs are 
available in the market, while a large number of 
new mAb drugs under development [51]. These 
drugs have always been very expensive and 
almost un-affordable by patients. In the absence 
of competition (generic), the sale of the first 
generation mAbs is quite good in terms of safety 
and price. However, with the high demand of 
specialty pharmaceuticals, steps have been 
taken to transform the manner in which mAbs are 
produced, commercialised and marketed. This 
has made mAb drug therapies a financial burden 
on patients, requiring some eminent health plans 
and step-wise therapies to resolve [52]. Some 
mAb drugs (e.g Bevacizumab) after repeated use 
were found to be widely available and cheaper 
than other agents (e.g Ranibizumab®), while 
demonstrating similar efficacy. This is because of 
the competition between improved mAb and a 
previously established product, which  requires a 
comparative clinical assessment for justification 
[53]. 
 
Future prospects of monoclonal antibodies lie in 
improvements and beneficial modifications of 
therapeutic mAbs, so as to reduce their harmful 
effects as antibody-based drugs. Monoclonal 
antibodies can also be further modified in order 
to have improved effects, through the 
possibilities of conjugated antibodies with 
coupling effector molecules [54].  The majority of 
mAbs from the early transgenic mice platform still 
remain murine in nature. These strains, despite 
their profound defects in B-cell development, 
they also remain to contain the necessary factors 
for immunoglobulin gene function, transcription 
and immunoglobulin gene recombination [55]. 
Chimeric antibodies, on the other hand, despite 
their limitation for therapeutic purpose, they are 
useful standardization reagents in diagnostic 
assays [56]. The XenoMouse strains were the 
first engineered mice with a majority of both 
human VH and VK repertoires, causing them to 
offer superior genetic stability [25]. This is seen 
as a benefit in design of potential therapeutic 
antibody with or without the effector function. 
About five fully human mAbs from XenoMouse 
strains have been used in human therapy [57]. 
 
Efforts to minimize non-human sequences of 
therapeutic mAbs involve immunogenicity, such 
as that seen in antibody fragments, which are 
usually less immunogenic due to their lack of Fc 
domain. In order to increase mAbs efficacy, the 
treatment of antibody fragments with 
polyethylene glycol (PEG) has also been applied 
[58]. The plasma half-life of IgG isotypes have 
also been reported to increase by developing 
antibodies through phage display platforms, and 
with noticeable increased affinity [59]. Binding 
affinity of an antigen can be up-graded through 
phage display libraries to isolate antibodies with 
strong affinities for the antigen, which 
consequently improves their therapeutic 
potentials [60]. 
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Although the first mAbs approved as human 
therapeutic agent were generally reported to be 
intolerable as therapeutics, advances in 
hybridoma technology have resulted in mAbs 
that are currently more effective and safe. Many 
of these new generation mAbs have been 
approved for human therapy. Multiple 
engineering efforts have led to the evolution of 
modified therapeutic antibodies in the hope of 
improving their efficacy and safety as antibody-
based drugs. These efforts include antibody 
chimerization, humanization and the 
development of fully human antibodies. The 
ability to engineer variable regions that encode 
multiple specificities into a single molecular entity 
has been an advantage for optimizing antigen-
binding capabilities. There is no doubt that the 
future of mAbs will sway the treatment of 
infectious diseases, cancers and other conditions 
like Alzheimer and Parkinsonism. Whether 
therapeutic mAbs will be commercially more 
abundant and affordable in the near future, is in 
part, a matter of rapid advances in biotechnology 
and biomolecular sciences as well as the 
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